Cancer, Solid Tumor
Conditions
Keywords
thyrosine kinase inhibitor, phosphokinase creatinin, myalgia
Brief summary
This study describes the elevation of CPK in patient treated for solid tumors by TKI
Interventions
BIOLOGICALCPK dosage
CPK dosage during a blood sample realized at least one week after the begining of the treatment
OTHERClinical exam
Examination of the patient for myalgia, cramps, medical history and concomitant medication
Sponsors
Centre Oscar Lambret
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with solid tumor treated by inhibitor of tyrosin kinase for at least 1 week * Patient examined AND with a routine blood test planned * Patient informed of procedure for the study who was not opposed to it
Exclusion criteria
* Patient treated for malignant hemopathy * Patient no treated by inhibitor of thyrosine kinase or for less than 1 week * Patients with no routine blood laboratory tests planned
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the prevalence of the CPK increase | Within 3 days after a clinical exam | Dosage of CPK during standard blood sampling. The increase of CPK is defined when CPK value \> USL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Correlation myalgia/CPK increase | During the clinical exam | To determine the correlation between myalgia and CPK blood, taking into account the risk factors leading to CPK increase |
Countries
France
Contacts
PRINCIPAL_INVESTIGATORAntoine ADENIS, MD, PhD
Centre Oscar Lambret
Outcome results
None listed